NRIX vs. VRNA, GRFS, TGTX, KRYS, SWTX, BHVN, RXRX, PTCT, OGN, and RARE
Should you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Verona Pharma (VRNA), Grifols (GRFS), TG Therapeutics (TGTX), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.
Nurix Therapeutics vs.
Verona Pharma (NASDAQ:VRNA) and Nurix Therapeutics (NASDAQ:NRIX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
In the previous week, Verona Pharma had 6 more articles in the media than Nurix Therapeutics. MarketBeat recorded 8 mentions for Verona Pharma and 2 mentions for Nurix Therapeutics. Verona Pharma's average media sentiment score of 0.88 beat Nurix Therapeutics' score of 0.00 indicating that Verona Pharma is being referred to more favorably in the media.
Verona Pharma has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500.
Verona Pharma has higher earnings, but lower revenue than Nurix Therapeutics. Verona Pharma is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Verona Pharma has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -354.85%. Nurix Therapeutics' return on equity of -53.65% beat Verona Pharma's return on equity.
85.9% of Verona Pharma shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Comparatively, 7.2% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Verona Pharma received 248 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. Likewise, 80.84% of users gave Verona Pharma an outperform vote while only 79.41% of users gave Nurix Therapeutics an outperform vote.
Verona Pharma presently has a consensus target price of $57.14, indicating a potential downside of 15.92%. Nurix Therapeutics has a consensus target price of $31.81, indicating a potential upside of 88.57%. Given Nurix Therapeutics' higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Verona Pharma.
Summary
Verona Pharma beats Nurix Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Nurix Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nurix Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRIX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free NRIX Stock Alerts